ICER updates cost-effectiveness estimates for CGRP inhibitors for migraines

ICER released an evidence report May 31 evaluating calcitonin gene-related peptide (CGRP) inhibitors for migraine prevention that calculated more favorable long-term cost-effectiveness ratios than in its April draft evidence report. ICER updated the

Read the full 331 word article

User Sign In